BWA
DNLI icon

Basecamp Wealth Advisors’s Denali Therapeutics DNLI Stock Holding History

Basecamp Wealth Advisors’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$437 Hold
17
– – ﹤0.01% 1654
2026
Q1 		$326 Sell
17
-14
-45% -$279 ﹤0.01% 1805
2025
Q4 		$512 Buy
+31
New +$523 ﹤0.01% 1633

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Basecamp Wealth Advisors's DNLI Position: Q2 2026 in Review

Basecamp Wealth Advisors held its Denali Therapeutics (DNLI) position steady in Q2 2026 at 17 shares worth $437. The position accounts for ﹤0.01% of the portfolio, ranked #1654.

Basecamp Wealth Advisors first reported a position in DNLI in Q4 2025 and has held it in 3 quarters since. The position peaked at $512 in Q4 2025. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Basecamp Wealth Advisors held 17 shares of Denali Therapeutics worth $437 as of Q2 2026.
  • Basecamp Wealth Advisors left its Denali Therapeutics share count unchanged in Q2 2026.
  • Denali Therapeutics made up ﹤0.01% of Basecamp Wealth Advisors's portfolio in Q2 2026, its #1654 holding.
  • Basecamp Wealth Advisors first reported a position in Denali Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Basecamp Wealth Advisors's Denali Therapeutics position peaked at $512 in Q4 2025.
  • 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Basecamp Wealth Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.